Bray Capital Advisors Iovance Biotherapeutics, Inc. Transaction History
Bray Capital Advisors
- $353 Million
- Q4 2024
A detailed history of Bray Capital Advisors transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Bray Capital Advisors holds 43,290 shares of IOVA stock, worth $230,302. This represents 0.09% of its overall portfolio holdings.
Number of Shares
43,290Holding current value
$230,302% of portfolio
0.09%Shares
1 transactions
Others Institutions Holding IOVA
# of Institutions
319Shares Held
244MCall Options Held
3.77MPut Options Held
1.7M-
Vanguard Group Inc Valley Forge, PA27.5MShares$146 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY26.6MShares$142 Million6.53% of portfolio
-
Mhr Fund Management LLC New York, NY24MShares$128 Million28.52% of portfolio
-
Black Rock Inc. New York, NY21.2MShares$113 Million0.0% of portfolio
-
State Street Corp Boston, MA13.2MShares$70.2 Million0.01% of portfolio
About IOVANCE BIOTHERAPEUTICS, INC.
- Ticker IOVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 157,800,992
- Market Cap $840M
- Description
- Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...